-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Agilon Health (NYSE:AGL) Versus Lisata Therapeutics (NASDAQ:LSTA) Critical Analysis
Agilon Health (NYSE:AGL) Versus Lisata Therapeutics (NASDAQ:LSTA) Critical Analysis
agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Get agilon health alerts:Volatility & Risk
agilon health has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Valuation and Earnings
This table compares agilon health and Lisata Therapeutics' gross revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
agilon health | $1.83 billion | 3.63 | -$406.49 million | ($0.26) | -62.08 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.21 |
Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
agilon health | -4.30% | -9.31% | -5.72% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for agilon health and Lisata Therapeutics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
agilon health | 0 | 1 | 7 | 0 | 2.88 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
agilon health currently has a consensus price target of $28.38, suggesting a potential upside of 75.81%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 492.89%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than agilon health.
Summary
Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.
About agilon health
(Get Rating)
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.
agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Agilon Health(紐約證券交易所代碼:AGL-GET Rating)和李薩塔治療公司(Lyata Treateutics:LSTA-GET Rating)都是醫療公司,但哪種投資更好?我們將根據分析師推薦的收益、風險、股息、盈利能力、機構所有權和估值對這兩家公司進行對比。
Institutional & Insider Ownership
機構與內部人持股
6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
李薩塔治療公司6.0%的股份由機構投資者持有。Agilon Health 3.3%的股份由內部人士持有。相比之下,李薩塔治療公司2.2%的股份由內部人士持有。強大的機構持股表明,對衝基金、大型基金管理公司和捐贈基金相信,一家公司的長期表現將好於大盤。
Volatility & Risk
波動性與風險
agilon health has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Agilon Health的貝塔係數為0.78,這意味着其股價的波動性比標準普爾500指數低22%。相比之下,李薩塔治療公司的貝塔指數為0.97,這意味着其股價的波動性比標準普爾500指數低3%。
Valuation and Earnings
估值和收益
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
agilon health | $1.83 billion | 3.63 | -$406.49 million | ($0.26) | -62.08 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.21 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
雅居隆健康 | 18.3億美元 | 3.63 | -4.0649億美元 | ($0.26) | -62.08 |
利薩塔治療公司 | 不適用 | 不適用 | -2,747萬元 | ($12.23) | -0.21 |
Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
利薩塔治療公司的收入低於Agilon Health,但收入高於Agilon Health。Agilon Health的市盈率低於李薩塔治療公司,這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.
此表比較了Agilon Health和Lisata Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
agilon health | -4.30% | -9.31% | -5.72% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
淨利潤率 | 股本回報率 | 資產回報率 | |
雅居隆健康 | -4.30% | -9.31% | -5.72% |
利薩塔治療公司 | 不適用 | -29.53% | -27.96% |
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for agilon health and Lisata Therapeutics, as reported by MarketBeat.
據MarketBeat報道,這是對雅吉隆健康公司和麗莎塔治療公司最近的評級和建議的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
agilon health | 0 | 1 | 7 | 0 | 2.88 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
雅居隆健康 | 0 | 1 | 7 | 0 | 2.88 |
利薩塔治療公司 | 0 | 0 | 2 | 0 | 3.00 |
agilon health currently has a consensus price target of $28.38, suggesting a potential upside of 75.81%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 492.89%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than agilon health.
Agilon Health目前的共識目標價為28.38美元,暗示潛在上行空間為75.81%。利薩塔治療公司的共識目標價為15美元,暗示潛在上漲492.89%。鑑於李薩塔治療公司更高的共識評級和更高的可能上行空間,分析師們顯然認為利薩塔治療公司比阿吉隆健康公司更有利。
Summary
摘要
Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.
在兩隻股票之間的13個因素中,李薩塔治療公司在7個因素上擊敗了Agilon Health。
About agilon health
關於阿吉隆健康
(Get Rating)
(獲取評級)
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Agilon Health,Inc.通過美國社區的初級保健醫生為老年人提供醫療服務。截至2021年12月31日,它為大約23.8萬名高級成員提供服務,其中包括18.63萬名聯邦醫療保險優勢成員和5.17萬名聯邦醫療保險按服務收費受益人。該公司前身為Agilon Health Topco,Inc.,於2021年3月更名為Agilon Health,Inc.。Agilon Health,Inc.成立於2016年,總部設在德克薩斯州奧斯汀。
About Lisata Therapeutics
關於李薩塔治療公司
(Get Rating)
(獲取評級)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
利薩塔治療公司是一家臨牀階段的生物製藥公司,專注於開發細胞療法並將其商業化,以逆轉疾病和/或促進受損組織的再生。它的候選產品包括接受Sakigake指定的HONEDRA,用於治療嚴重肢體缺血的第二階段臨牀試驗;XOWNA,用於治療冠狀動脈微血管功能障礙的第二階段臨牀試驗;以及CLBS201,一種用於治療慢性腎臟疾病透析前患者的CD34+細胞療法。該公司前身為NeoStem,Inc.,並於2015年6月更名為Caladrius Biosciences,Inc.。該公司前身為Caladrius Biosciences,Inc.,並於2022年9月15日更名為李薩塔治療公司。利薩塔治療公司成立於1980年,總部設在新澤西州的巴斯金裏奇。
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《雅居倫健康日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Agilon Health及相關公司評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧